Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The current standard treatment approach for young patients with Positive Acute Lymphoblastic
Leukemia (Ph+ALL) is the combination of a chemotherapy protocol employing four to five
cytotoxic agents typically used for ALL together with imatinib. It is recommended to propose
allogeneic Standard Induction and Consolidation Therapy (SCT) to all eligible patients with a
suitable donor and to continue imatinib with or without additional therapy in patients not
undergoing SCT.
This protocol is a study for newly diagnosed Philadelphia chromosome positive acute
lymphoblastic leukemia in patients aged 18 to 55 years.
The objective of this strategy is to improve the overall results in the treatment of adult
ALL with the addition of specific molecules to the common chemotherapeutic schedule.